natgillin/translations-raw huggingface dataset:
The eukaryotic host cell of claim 13 which is a mammalian host cell. A method of producing an anti-OX40 antibody, comprising: (a) culturing the host cell of claim 14 and (b) recovering the anti-OX40 antibody. 
Postupak proizvodnje protutijela protiv OX40, naznačen time što se sastoji u: (a) uzgoju stanice domaćina u skladu s patentnim zahtjevom 10 ili patentnim zahtjevom 11; i (b) prikupljanju protutijela protiv OX40.
The method according to one of the preceding variants, further comprising the step of ignoring anchor acceleration values measured during intervals when the anchor is deemed to be at rest. 
2. = Postupak prema patentnom zahtjevu 1, koji pored toga obuhvaća i korak ignoriranja vrijednosti ubrzanja sidra mjerene u intervalima kada se smatra da je sidro u mirovanju.
A hydrogenated cannabis oil for use in a method of treatment to regress tumors in a cancer patient, wherein the hydrogenated cannabis oil comprises a hydrogenated acid selected from the group consisting of hydrogenated A-9-tetrahydrocannabinolic acid, A-9-cannabidiolic acid and mixtures and blends thereof. 
Hidrogenirano kanabisovo ulje, naznačeno time, da se upotrebljava u postupku liječenja regresijskog tumora kod pacijenta koji ima rak, pri čemu hidrogenirano kanabisovo ulje obuhvaća hidrogeniranu kiselinu odabranu iz skupine koju čine hidrogenirana A-9-tetrahidrokanabinolna kiselina, hidrogenirana A-9-kanabidiolna kiselina, te njihove mješavine i smjese.
A packaging according to claim 1, at least an area, and preferably the entire area, of said surfaces facing the inside of the packaging having a 3D roughness Ra greater than about 15µm, preferably greater than 20µm, more preferably greater than 40µm and most preferably greater than 53µm. 
barem područje, a po mogućnosti čitavo područje navedene površine perifernog bočnog zida sučelice unutarnjeg dijela pakiranja ima stupanj grubosti 3D Ra od najviše 70 µm.
To obtain evenly distributed discrete bonding spots or bonding areas along the contact path the corresponding number of radially movable pressing elements may also be evenly distributed along the circumference of the first member. 
Da bi se dobile jednoliko raspoređene točke spajanja ili područja spajanja, također se jednoliko rasporedi odgovarajući broj radijalno pomičnih tlačnih elemenata duž oboda prvog ili drugog elementa,
Cytotoxic modular antibody, specifically binding to a cell surface target with a binding affinity of kd<10-8 M, which is an antigen binding Fc (Fcab) of an antibody molecule with effector function, which is at least one of ADCC, ADCP and CDC activity, with an antigen binding site engineered in the loop region of a CH3 domain to bind said cell surface target, wherein the cell surface target is a receptor of the erbB class. 
Citotoksično modularno protutijelo, naznačeno time, da se specifično veže za cilj na površini stanice s afinitetom vezanja od Kd<10-8 M, pri čemu je to Fc (Fcab) koji veže antigen molekule protutijela s funkcijom efektora, koje ima barem jednu od ADCC, ADCP i CD aktivnosti, s mjestom vezanja antigena uređenim na području čvorova od domene CH3 za vezanje na spomenuti cilj na površini stanice, pri čemu cilj na površini stanice je receptor iz razreda erbB.
The pharmaceutical product according to Claim 3 for treating or reducing a disease including injury to central nervous system, such as brain head trauma, and spinal cord injury, cerebral infarction, ischemic heart diseases and peripheral arterial occlusive diseases, or after-effects of these diseases. 
Farmaceutski pripravak kako je definiran u zahtjevu 5 naznačen time da je za upotrebu za liječenje ili smanjenje bolesti, uključujući ozljede središnjeg živčanog sustava, kao što su trauma glave i ozljeda leđne moždine, moždani infarkt, ishemijske bolesti srca 1 bolesti začepljenja perifernih arterija, ili posljedica navedenih bolesti.
A pharmaceutical formulation for use in the treatment of respiratory disease according to any of Claims 1 to 7 wherein the respiratory disease is asthma. 
Farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 1 do 7, gdje spoj sa formulom (I) je odabrano od:
A composition comprising (a) a plurality of intact, bacterially-derived minicells, wherein each minicell of said plurality encompasses regulatory RNA that is packaged in said minicell, and (b) a pharmaceutically acceptable carrier therefor, wherein there is an absence from said minicells of a construct for in situ expression of said regulatory RNA, wherein said regulatory RNA is selected from the group consisting of siRNA, miRNA and shRNA, and wherein said plurality contains a therapeutically effective amount of said regulatory RNA. 
HR P20150328 T1 so PATENTNI ZAHTJEVI Pripravak koji sadrži (a) mnoštvo intaktnih, bakterijski dobivenih mini-stanica, gdje svaka od tog mnoštva ministanica sadrži regulatornu RNA pakiranu u tim mini-stanicama 1 (b) farmaceutski prikladan nosač za nju, gdje u tim mini-stanicama nema konstrukta za in situ ekspresiju regulatorne RNA, pri čemu se regulatorna RNA izabire iz skupine koja obuhvaća siRNA, miRNA i shRNA, 1 gdje to mnoštvo sadrži terapijski učinkovitu količinu regulatorne RNA.
The compound of claim 5, wherein R5 is selected from the group consisting of H,-C(=O)N(R9)2, and -CN. 
Spoj prema zahtjevu 6, naznačen time da R5 je odabran iz skupine koja sadrži H, -C(=O)N(R9)2, te -CN.
is selected from the group consisting of hydrogen and alkylsulfonyl; or 
R je odabran iz grupe koja se sastoji od vodika i alkila; ili
8 is a schematic partial section of the discharge device with the metered dose valve according to the second embodiment of the present invention in the first position; 
prikazuje shematski djelomičan presjek naprave za pražnjenje s ventilom za odmjeravanje doze prema drugoj izvedbi predloženog izuma u prvom položaju; slika 9
a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:119 and/or a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:118; 
(DD VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 119i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 118;
converting a compound of formula [46] to a compound of formula [47] wherein R1 and R6 are defined above; 
(c) prevođenju spoja formule [46] u spoj formule [47] i RL gdje su R' i R* definirani gore;
In one embodiment, the mouse further comprises a humanized IL-6 gene. In one embodiment, the mouse comprises a replacement at an endogenous mouse IL-6 locus of a mouse IL-6 gene with a human IL-6 gene. 
Genetički modificirani miš prema zahtjevu 6, naznačen time da dodatno sadrži humanizirani IL-6 gen koji sadrži zamjenu na endogenom lokusu mišjeg IL-6 za mišji gen koji kodira IL-6 s ljudskim genom koji kodira ljudski IL-
A dosage form according to claim 8, characterized in that it is suitable for oral, intravenous, intraarterial, intraperitoneal, intradermal, transdermal, intrathekal, intramuscular, intranasal, transmucosal, subcutaneous, or rectal administration. 
Oblik doziranja prema zahtjevu 6, naznačen time što je prikladan za oralnu, intravenoznu, intraarterijalnu, intraperitonealnu, intradermalnu, transdermalnu, intratekalnu, intramuskularnu, intranazalnu, transmukozalnu, potkožnu ili rektalnu primjenu.
The method according to claim 1, wherein the gabapentin is present in quantities equal to 98% by weight based on the total weight of the granulate, the polyethylene glycol being 2% by weight based on the total weight of the granulate. A method for producing a gabapentin pharmaceutical composition in a tablet form comprising 
Granulat prema zahtjevu 1, naznačen time što je gabapentin prisutan u količinama jednakim 98% težinski, a PEG je2%. 5. Farmaceutska smjesa gabapentina, naznačena time što je u obliku tablete dobivene komprimiranjem granulata iz zahtjeva 1.
Preparation of Seed Crystals of Compound (I) 
Postupak pripreme spoja formule (I) iša
The first and second adhesive portions 102, 104 may together form a strip of adhesive extending along the first surface 106 perpendicular to the first fold 108, as shown in figure 4 . 
Metoda u skladu s patentnim zahtjevom 4, pri čemu navedeni prvi i drugi prianjajući dijelovi zajedno oblikuju traku prianjajućeg produljenja duž navedene prve površine paralelno s navedenim prvim naborom.
Preferred changes for muteins in accordance with the present invention are what are known as “conservative” substitutions. 
Poželjne promjene za muteine, u skladu sa ovim izumom, poznate su pod nazivom "konzervativne" supstitucije.
An immediate release, oral pharmaceutical formulation comprising in percentage by weight: 
Oralna farmaceutska formulacija s trenutnim otpuštanjem, naznačena time, da je u obliku granulata od 10 mg, koji sadrži po masi:
Method according to claim 6, where further a drain valve located between the closed system valves and upstream the filter element, is opened towards a lower pressure area, in order to release the mechanically separated higher viscosity fraction from the filter and through the drain valve. 
– gdje se dodatno ispusni ventil nalazi između zatvorenih sustavnih ventila i uzvodno od filtarskog elementa, te se otvara prema području nižeg tlaka, radi ispuštanja mehanički odvojene visokoviskozne frakcije iz filtra i kroz ispusni ventil;
A pharmaceutical composition of claim 19, wherein said additional active agent is selected from IGF-1, IGF-2 or active variants of IGF-1 or IGF-2, an anti-myostatin antibody, a myostatin propeptide, a myostatin decoy protein that binds ActRIIB but does not activate it, a beta 2 agonist, a Ghrelin agonist, a SARM, GH agonists/mimetics, and follistatin. 
Farmaceutski sastav prema zahtjevu 20, naznačen time, da navedeno dodatno djelotvorno sredstvo je odabrano od sljedećih: IGF-1, IGF-2 ili varijante od IGF-1 ili IGF-2, protutijelo anti-miostatin, miostatin-propeptid, miostatin-decoy-protein koji veže ActRIIB, ali ga ne aktivira, beta 2-agonist, Ghrelin-agonist, SARM, GH-agonisti/mimetici i folistatin.
The total manufacturing costs, including the cost for the raw material is at least 20 % lower than in the standard process (European - style process). 
Ukupni troškovi proizvodnje, uključujući trošak za sirovi materijal, su najmanje 20 % niži nego kod standardnog postupka (postupak na europski način).
Eugragit L 30 D55, 419.25 g, which is in the form of a 30% aqueous dispersion was screened through a U.S. Sieve No. 
Eugragit L 30 D55, 419.25 g, koji je u obliku 30%-tne vodene disperzije se propusti kroz mrežasto U.S. sito br.
wherein at least one processing agent is added before, during or after said aqueous calcium carbonate containing mineral slurry of step a) is contacted with said acid of step b) and with said CO2 generated in situ and/or supplied externally of step c), the processing agent is dosed in one or more steps to said aqueous calcium carbonate containing mineral slurry, the processing agent is added in amounts of up to 8 wt.% based on the dry weight of the slurry, and the at least one processing agent is selected from the group comprising ferrous sulfate, ferric sulfate, ferrous chloride, ferric chloride, aluminum sulfate, and/or their hydrated forms, silicates, water-soluble cationic polymers, water-soluble amphoteric polymers, water-soluble non-ionic polymers and combinations thereof, as well as seeds of precipitated calcium carbonate (PCC), or surface reacted calcium carbonate, or ball-shaped surface reacted calcium carbonate comprising mineral. 
proizvoljno uklanjanje vode iz vodene suspenzije; naznačen time da se barem jedno sredstvo za obradu dodaje prije, tijekom ili poslije dovođenja u kontakt navedene vodene suspenzije koja sadrži kalcijev karbonat koji sadrži mineral iz koraka a) s navedenom kiselinom iz koraka b) i s navedenim CO, nastalim na licu mjesta i/ili koji se dobavlja iz vanjskog izvora iz koraka c), te pri čemu se barem jedno sredstvo za obradu bira iz skupine koju čine željezni sulfat, željezov sulfat, željezni klorid, željezov klorid, aluminijev sulfat, i/ili njihovi hidratni oblici, te pri čemu se sredstvo za obradu dodaje u količinama sve do 8 tež.% na bazi suhe težine suspenzije.
Formulation for anticorrosion paints and coatings according to claim 3, wherein the amount of said nanoparticles is lower than 1% by weight, based on the total weight of the formulation. 
Sastav antikorozivnih slika i premaza sukladno zahtjevu 1 ili 2, naznačeno time da je težinski udio navedenih nanočestica niži od 1%, uzimajući u obzir u obzir ukupnu težinu sastava
The receptor complex mediating the biological activities of IL-6 consist of two distinct membrane bound glycoproteins, an 80 kDa cognate receptor subunit (IL-6R) and a 130 kDa signal-transducing element (gp130, CD130). 
Receptorski kompleks koji posreduje u biološkim aktivnostima IL-6 sastoji se od dva zasebna glikoproteima vezana za membranu, receptorske podjedinice od 80 kDA (IL-6R) i elementa za prijenos signala od 130 kDA (gp130, CD130).
Equipment for controlling, measuring and reporting a physical quantity of a container containing a fluid under pressure according to the previous claims characterized in that to each position of the dosing knob (S1.1) corresponds the selection of a slot (S1.1.2) and one of the sensitive elements (S1.1.1). 
Metoda za kontroliranje, mjerenje i izvještavanje vrijednosti brzine toka fluida koja je određena pomoću opreme za kontroliranje, mjerenje i izvještavanje fizičke veličine posude koja sadrži fluid pod pritiskom za koju se traži zaštita u prethodnim patentnim zahtjevima okarakterizirana time da:
depleting human alpha beta TCR+ T cells from said donor source to produce a depleted donor source; adjusting the number of human alpha beta TCR+ T cells in said depleted donor source to between 2.0 x 106 and 5.0 x 106 human alpha beta TCR+ T cells per kg recipient body weight, 
HSCs); crpljenje humanih alfa beta TCR+ T stanica iz navedenog donorskog izvora kako bi se proizveo iscrpljeni donorski izvor; podešavanje broja humanih alfa beta TCR+ T stanica u navedenom iserpljenom donorskom izvoru na između 2.0 x 10" i 5.0 x 10" humanih alfa beta TCR+ T stanica po kg tjelesne težine primatelja, čime se dobiva terapeutski stanični pripravak za primjenu na primatelju, naznačen time da se u postupku ne koristi humani zametak.
Examples of a small molecule drug which may be conjugated with the carrier of the present invention and which are encompassed herewith, includes for example Taxol, a Taxol derivative, vinblastine, vincristine, etoposide, doxorubicin, cyclophosphamide, Taxotere, melphalan, chlorambucil, pharmaceutically acceptable salts, and combination thereof as well as any drug which may be a P-gp substrate, whereby Taxol is, according to the invention, included in the conjugate of the present invention. 
(b) anti-kancerogeni lijek odabran iz skupine koja sadrži Taxol, vinblastin, vinkristin, etoposide, doksorubicin, ciklofosfamid, Taxoter, melfalan, te klorambucil, ili antitijelo, fragment antitijela, ili peptidni ili proteinski lijek, pri čemu je navedeni anti-kancerogeni lijek, navedeno antitijelo, navedeni fragment antitijela, ili navedeni peptidni ili proteinski lijek konjugiran na navedeni polipeptid.
The reaction mixture may further contain carbon tetrachloride, for example in an amount up to about 50 wt% of the reaction mixture, for example from about 3 to about 30 wt%. The ferric chloride is preferably present in the mixture in a catalytic amount, preferably 25000 ppm or lower, for example about 5000 ppm, 2000 ppm, or 1000 ppm or lower. 
Postupak iz patentnog zahtjeva 1, pri čemu reakcijska smjesa nadalje obuhvaća ugljikov tetraklorid. Postupak iz patentnog zahtjeva 2, pri čemu je ugljikov tetraklorid prisutan u količini do 50 težinskih postotnih udjela reakcijske smjese. Postupak iz patentnog zahtjeva 1, pri čemu je željezov(IlI) klorid prisutan u reakcijskoj smjesi u količini koja je u rasponu od 30 do 1000 ppm.
The method of claim 25, wherein the patient is provided treatment, and the method further comprises the steps of obtaining one or more patient samples to determine the effect of the treatment, and continuing treatment until the hematologic malignant proliferative disease is reduced or eliminated. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 23, pri čemu je subjektu osigurano liječenje, a metoda dalje obuhvaća korake dobivanja jednog ili više uzoraka od subjekta kako bi se odredio učinak liječenja te daljnje liječenje do smanjenja ili uklanjanja akutne mijeloične leukemije (AML).
A product for the biological control of phytopathogenic fungi and stimulating plant growth according to claim 2, wherein the viable cells are in the form of spores. 
Proizvod za biološku kontrolu fitopatogenih gljivica i stimuliranje rasta biljaka temeljem zahtjeva 2, naznačen time što su navedene održive stanice u obliku spora.
The composition of solution for wood preservation according to the present invention is optimized using two criteria, after extensive laboratory testing. 
Pripravak otopine za konzerviranje drva prema ovom izumu je optimiziran upotrebom dvaju kriterija, nakon opsežnog laboratorijskog testiranja.
about 0.8% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 69% metformin hydrochloride; about 3% hydroxypropyl cellulose; about 20% microcrystalline cellulose; about 6.5% hydroxypropyl cellulose, low substituted; and about 0.8% magnesium stearate; 
(H) 0.8% dapagliflozina ili dapagliflozin (S) propilen glikol hidrata; 69% metformin hidroklorida; 3% hidroksipropil celuloze; 20% mikrokristalne celuloze; 6.5% hidroksipropil celuloze, nisko supstituirane; i 0.8% magnezijevog stearata;
The lithium accumulator of claim 1 to 13 wherein the electro-insulating material (55) is elected from the group of ceramic oxides Al2O3, SiO2, ZrO2 polytetrafluoroethylene, polyfluoride-hexafluoropropene, polycycloolefine. 
Litijev akumulator sukladno zahtjevu 1 do 13, u kome se elektro-izolacijsku materijal (55) odabire iz skupine keramičkih oksida Al₂O₃, SiO₂, ZrO₂ politetrafluoretilene, polifluorid-hexafluoropropene, policiclolefine.
IL-18BP is highly glycosylated and consequently is more acidic (isoelectric point of about 3) and less hydrophobic than immunoglobulins. 
IL-18BP je visokoglikozilirani protein te je zbog toga i kiseliji (izoelektrična točka iznosi otprilike 3) 1 manje hidrofoban od imunoglobulina.
Apparatus for carrying out a process according to claim 7, wherein said first and second mills are oversized in order to avoid overheating of the material. 
Uređaj (10) za provođenje postupka prema zahtjevu 7, naznačen time da su navedeni prvi i drugi mlinovi (1, 1) predimenzionirani da bi se izbjeglo pregrijavanje materijala.
a solution, comprising at least one sort of lignin and also at least one fibre-forming polymer selected from the group consisting of polyacrylonitrile and/or polyacrylonitrile-copolymers in at least one solvent, 
otopina, koja se sastoji od barem jedne vrste lignina i barem jednog polimera koji tvori vlakna odabranog iz skupine koja se sastoji od celuloze ili derivata celuloze u barem jednoj otopini, odabranoj iz skupine tercijarnih amin oksida i/ili ionskih tekućina,
Within a preferred embodiment the transcription rate is at least 2-fold higher when growing a yeast host cell, preferably S. cerevisiae, transformed with at least one recombinant DNA fragment comprising an oligonucleotide according to the present invention on at least two substrates selected from the group consisting of glucose, mannose, fructose, galactose, xylose, arabinose, sucrose, trehalose, raffinose, glycerol, ethanol, acetate and lactate. 
Oligonukleotidna sekvenca prema zahtjevu 1 ili 2 naznačena time da je razina transkripcije DNA fragmenta u stanicama kvasca domaćina uvećana barem dvostruko kada se uzgajanje stanica kvasca domaćina transformirana s najmanje jednim rekombiniranim fragmentom DNK koji sadrži oligonukleotid na barem dva supstrata izabranih iz grupe koja sadrži glukozu, manozu, fruktozu, galaktozu, ksilozu, arabinozu, saharozu, trehalozu, rafinozu, glicerol, etanol, acetat i laktat.
A use of a compound of any one of claims 1-8 in the preparation of a medicament for preventing or treating infection by HCV in a subject in need thereof. 
Spoj prema patentnom zahtjevu 13, naznačen time što se koristi za primjenu u postupku prevencije ili liječenja HCY infekcije.
The lozenges may then be coated with a glazing or anti-sticking agent such as Capol. 
Tablete-pastile zatim mogu biti obložene glazurom ili sredstvom protiv ljepljenja kao što je kapol.
1 shows a partially sectioned plan view of a device for opening flexible containers in accordance with the invention, in a first operative configuration; FIG. 2 shows a partially sectioned plan view of the device shown in FIG. 
Slika 1 - prikazuje nacrt uređaja za otvaranje savitljivih vrećica koji je u skladu s ovim izumom u prvom radnom položaju; uređaj je prikazan djelomično u presjeku;
The make and break threaded connection of Claim 1, wherein the average thread height (h1, h2, h3, h4) of the pin threads is about 0.04 inches or greater. 
„Make and break“ priključak s navojem iz zahtjeva 1, naznačen time da je prosječna visina navoja (h1, h2, h3, h4) klinastih navoja oko 0,04 inčeva ili veća.
The transfer liquid bath is adapted to provide a thickness of the transfer liquid corresponding to the wave-length of the resonance frequency of the sonotrode 41 by the side walls 42 extending to the wave-length of the resonance frequency of the sonotrode 41 in perpendicular to the sonotrode surface 40 . 
Upotreba prema zahtjevu 14, naznačeno time da ultrazvučni uređaj ima površinu ultrazvučnog uređaja (40) koja tvori jedan zid transferne tekuće kupke, a visina transferne tekuće kupke okomite na površinu (40) je predodređena na jednu valnu duljinu ili inegralni višekratnik valne duljine ultrazvuka.
for fiber-optic umbilical lines, set the communication frequencies for sending and receiving at applicable high band, receiving ship to shore communication, and low band, sending shore to ship communication, frequencies; and that by activating the transfer switch for switching from a shore type control module to a ship type control module, the control module is arranged to automatically revert to the settings corresponding to those of a ship type control module. 
za optičke umbilikalne kabele, postavljanje komunikacijskih frekvencija za slanje i primanje na prikladni visoki frekvencijski pojas, prijem komunikacije brod-obala, i niski frekvencijski pojas, slanje komunikacije obala-brod; i to aktivacijom sklopke za prebacivanje za prebacivanje iz obalnog tipa upravljačkog modula u brodski tip upravljačkog modula, upravljački modul prilagođen je da se automatski vraća na postavke koje odgovaraju onima na brodskom tipu upravljačkog modula.
The medicament of claim 1, wherein the medicament comprises a composition comprising said compound of (I) and a composition comprising said drug of (II), which are separately formulated, and the composition of said compound of (I) is provided for use in combination with the composition of said drug of (II). 
Medikament prema zahtjevu 1, naznačen time, da medikament obuhvaća jedan sastav koji obuhvaća navedeni spoj (I) i jedan sastav koji obuhvaća navedeni lijek (II), koji su formulirani odvojeno, te se sastav od navedenog spoja (1) pripravlja za uporabu u kombinaciji sa sastavom od navedenog lijeka (II).
wherein the outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria and a second polymeric material which has a pH threshold at pH 6 or above, and wherein the inner layer comprises a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being a polycarboxylic acid polymer that is at least partially neutralised with at least 10% of the carboxylic acid groups in the form of carboxylate anions. 
pri čemu vanjski sloj sadrži smjesu prvog polimernog materijala koji je osjetljiv na napad bakterija debelog crijeva i drugi polimerni materijal koji ima prag pH na pH 6 ili više, i pri čemu unutarnji sloj sadrži treći polimerni materijal koji je neionski polimer koji je topljiv u crijevnoj tekućini, ili gastrointestinalnoj tekućini, i najmanje jedan aditiv odabran iz puferskog sredstva i baze.